Statute Details
- Title: Health Products (Advertisement of Specified Health Products) Regulations 2016
- Act Code: HPA2007-S333-2016
- Legislative Type: Subsidiary legislation (SL)
- Enacting Authority: Health Sciences Authority (HSA) with Minister for Health approval
- Commencement: 1 November 2016 (as amended, current version as at 27 Mar 2026)
- Primary Enabling Provision: Section 72 of the Health Products Act (Cap. 122D)
- Key Definitions (Regulation 2): “specified health product”, “therapeutic product”, “prescription-only medicine”, “pharmacy-only medicine”, “non-public sector person”, “publish”, “sales promotion”, “qualified practitioner”, “relevant health professionals”
- Key Requirements: Regulations 3–5 (general requirements, exclusions, substantiation); Regulations 6–10 (disease/condition restrictions, prescription/pharmacy-only rules, unregistered products, sales promotions); Regulations 11–14 (professional/scientific info, reference/trade ads, informational statements, sales promotions involving registered products); Regulation 15 (HSA power to require copies)
- Schedules: First Schedule (classes of therapeutic products/CTGT product categorisation), Second Schedule (specified health products), Third Schedule (specified diseases or conditions)
What Is This Legislation About?
The Health Products (Advertisement of Specified Health Products) Regulations 2016 (“Advertisement Regulations”) set out Singapore’s detailed rules for advertising “specified health products” under the Health Products Act (Cap. 122D). In plain terms, the Regulations aim to ensure that marketing of health-related products is accurate, not misleading, and does not encourage unsafe self-treatment or inappropriate use.
The Regulations operate as a compliance framework for advertisers, licensees, and other parties who “publish” advertisements—whether through traditional media, digital platforms, or other forms of communication. They distinguish between different categories of health products (including therapeutic products) and different regulatory classifications of medicines (prescription-only vs pharmacy-only). This matters because the law imposes stricter controls on products that require professional oversight or are not intended for unsupervised consumer use.
Practically, the Regulations are designed to reduce public health risks arising from aggressive marketing claims. They also address the credibility of advertising content: where an advertisement makes claims of uniqueness, prominence, awards, or differentiating features, the advertiser must have evidence to substantiate those claims. The Regulations therefore combine “what you may not do” (prohibited content) with “what you must be able to prove” (substantiation).
What Are the Key Provisions?
1. Scope and baseline compliance (Regulation 3)
Regulation 3 provides the core structure: for the purposes of section 21(1) of the Health Products Act, an advertisement of a specified health product must (subject to modifications for certain types of advertising under Regulations 11–14) (a) comply with Regulations 4, 5 and 6; and (b) be undertaken in accordance with additional requirements depending on the product type. In particular, for most specified health products the advertisement must comply with Regulations 7, 9 and 10; for a therapeutic product only, it must comply with Regulation 8.
This is important for practitioners because it tells you how to “map” obligations. You start with the general prohibitions and substantiation rules, then apply the medicine-specific and product-specific restrictions. If you are advising on an advertisement campaign, you should identify the product category first (specified health product vs therapeutic product; prescription-only vs pharmacy-only), then check the relevant regulatory pathway.
2. Prohibited advertising content (Regulation 4)
Regulation 4 lists matters that an advertisement must not do. The prohibitions are broad and target common misleading or harmful marketing patterns. Key examples include: advertisements must not be likely to lead consumers to self-diagnose or inappropriately treat serious diseases; must not suggest that advice from a registered pharmacist or qualified practitioner is unnecessary; and must not imply that medical consultation or surgical operations are not necessary if the product is used.
The Regulation also prohibits claims that mislead about quality or efficacy (including by implication, emphasis, contrast or omission), and forbids comparisons or contrasts with other named specified health products or brands. It further restricts fear-based or distress-inducing advertising (e.g., language or images causing fear, alarm or distress about a disease or condition), and bans “miracle” or guaranteed cure-type claims (infallible, unfailing, magical, miraculous; certain, guaranteed or sure cure). Advertisements must not claim that the product is free of side effects, must not offer refunds or guarantee refunds, and must not falsely claim government or public authority endorsement.
Finally, Regulation 4 includes audience and endorsement restrictions: advertisements must not be directed principally at persons below age 14, and must not contain any endorsement or recommendation by healthcare professionals (or by celebrities/social/professional figures likely to encourage use). These provisions are particularly relevant for influencer marketing and celebrity endorsements, where the “endorsement” content can trigger a breach even if the product claims themselves are otherwise careful.
3. Substantiation of uniqueness and prominence claims (Regulation 5)
Regulation 5 addresses a frequent advertising tactic: differentiating a product by claiming it is unique, prominent, certified, award-winning, or otherwise superior to competing products. Where an advertisement contains such statements or features, the statement must be substantiated by facts or evidence.
For legal practice, this is a “proof obligation” embedded in the Regulations. It does not merely require that claims be “not false”; it requires evidence supporting the differentiating feature. Advisers should therefore ensure that marketing teams retain documentation (e.g., test reports, award criteria, certification details, comparative study data) that can be produced if the HSA requests substantiation.
4. Restrictions on promoting for specified diseases/conditions and medicine classification (Regulations 6–10)
While the extract provided truncates the later text, the Regulations’ structure and headings are clear and are central to compliance. Regulation 6 restricts promoting specified health products for specified diseases or conditions, and Regulation 7 prohibits advertisement of prescription-only medicines. Regulation 8 imposes a specific requirement for advertisements of pharmacy-only medicines by non-public sector persons (including prominent display of required information). Regulation 9 sets requirements for advertisements of unregistered specified health products. Regulation 10 governs sales promotions involving specified health products.
From a practitioner’s standpoint, the key takeaway is that Singapore’s advertising regime is classification-driven. Prescription-only medicines are generally not to be advertised to the public in the manner contemplated by the Regulations. Pharmacy-only medicines may be advertised, but with mandatory presentation requirements when advertised by non-public sector persons. Unregistered products face additional constraints, reflecting the broader regulatory requirement that products must be properly registered/authorised under the Health Products Act framework before being marketed.
5. Sales promotions and special advertising formats (Regulations 10–14)
The Regulations define “sales promotion” broadly to include sales campaigns (including door-to-door sales), exhibitions, competitions, or other activities intended to introduce, publicise, raise awareness, or increase visibility of a specified health product for the purpose of promoting sale or use. Regulation 10 restricts sales promotions involving specified health products, and Regulation 14 addresses sales promotions involving registered specified health products.
Regulations 11–13 then deal with other advertising categories: professional or scientific information advertising, reference and trade advertisements, and informational statements. These provisions matter when an advertisement is not a typical consumer-facing marketing message but instead takes the form of professional materials, trade communications, or informational statements. Practitioners should review whether the campaign is intended to fall within these modified rules, because the Regulations expressly “modify” the application of the general requirements depending on the advertising type.
6. Enforcement support: HSA power to require copies (Regulation 15)
Regulation 15 empowers the Authority to require, by written notice, any person who advertises (or causes advertisements to be advertised) to provide copies of advertisements. This is a practical enforcement tool: it enables the HSA to review content, verify substantiation, and assess compliance with the prohibitions and classification rules. Advisers should therefore ensure that marketing materials, scripts, creatives, and versions used in campaigns are retained and can be produced promptly.
How Is This Legislation Structured?
The Regulations are organised as follows:
- Regulation 1: Citation and commencement (1 November 2016; amended later by S 109/2021 effective 1 March 2021)
- Regulation 2: Definitions (key terms used throughout the Regulations)
- Regulation 3: Requirements for advertisement of specified health products (the “routing” provision)
- Regulation 4: Matters to be excluded in advertising specified health products (prohibited content)
- Regulation 5: Substantiation of uniqueness and prominence assertions
- Regulations 6–10: Product- and classification-specific restrictions (diseases/conditions; prescription-only prohibition; pharmacy-only requirements; unregistered products; sales promotions)
- Regulations 11–14: Modified rules for professional/scientific information, reference/trade advertisements, informational statements, and sales promotions involving registered products
- Regulation 15: Power of Authority to require copies of advertisements
- Schedules: First Schedule (relevant therapeutic product categorisation including CTGT product); Second Schedule (specified health products); Third Schedule (specified diseases or conditions)
Who Does This Legislation Apply To?
The Regulations apply to “advertisements” of “specified health products” and therefore bind persons who publish, cause to be published, or otherwise participate in advertising campaigns for such products. The definition of “publish” is intentionally broad and includes distributing, showing, displaying, exhibiting, issuing, disseminating, or broadcasting by any form of communication or in any manner.
They also distinguish between public sector persons and non-public sector persons. Several provisions—particularly those concerning prescription/pharmacy-only medicines and certain advertisement presentation requirements—are framed around whether the advertiser is a non-public sector person. In practice, this means that private companies, importers, manufacturers, wholesalers, retailers, and marketing agencies must carefully structure their campaigns to comply with the applicable restrictions and disclosure requirements.
Why Is This Legislation Important?
For practitioners, these Regulations are significant because they translate health-product regulatory policy into concrete advertising rules. Non-compliance can expose businesses to regulatory action and reputational harm, especially where advertising content is misleading, encourages self-treatment of serious conditions, or uses prohibited endorsement and fear-based messaging.
The Regulations also create a compliance workflow that is more than “avoid false claims.” They require evidence for certain marketing assertions (Regulation 5), impose classification-based restrictions (Regulations 6–9), and regulate promotional mechanics (Regulations 10 and 14). This means legal review must be integrated early in the marketing process—before creatives are finalised and before campaigns are launched across multiple channels.
Finally, the HSA’s power to require copies of advertisements (Regulation 15) underscores that enforcement is likely to be content-focused and documentation-supported. Businesses should therefore maintain a compliance file for each campaign: product classification evidence, registration status, substantiation documents, and archived versions of advertisements and scripts.
Related Legislation
- Health Products Act (Cap. 122D)
- Dental Registration Act (Cap. 76)
- Medical Registration Act (Cap. 174)
- Medicines Act
- Midwives Act
Source Documents
This article provides an overview of the Health Products (Advertisement of Specified Health Products) Regulations 2016 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.